

02/05/2004

12:03

TAKEDA PHARMACEUTICALS → USPTO GRP1600

NO. 195 001



RECEIVED
CENTRAL FAX CENTER

FEB 05 2004

OFFICIAL

TO: COMMISSIONER FOR PATENTS
ATTN: Group 1635/Examiner B. Whiteman
FAX: 1-703-872-9306
PHONE:
RE: 2519 USOP - Application. No. 09/673,958

FROM: Mark Chao, PhD, JD
DATE: February 5, 2004
PAGES: 5 including cover sheet
CC:

FAX MESSAGE:

Please find attached a Response under 37 CFR 1.111 regarding the above case.

TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
475 Half Day Road Lincolnshire, Illinois 60069 Phone: 847-383-3000

Please contact the sender if all pages are not received. NOTICE: This transmittal is strictly intended for delivery only to the person listed above. This facsimile transmission may contain confidential or otherwise privileged information which is subject to Attorney-Client and/or Attorney Work Product Privilege, the disclosure of which is strictly prohibited. If you have received this facsimile by mistake please contact the sender immediately, at the phone number listed above (collect call) for instructions as to the return or disposal of this transmission.

02/05/2004

12:03

TAKEDA PHARMACEUTICALS → USPTO GRP1600

NO. 195 D002

PTO/SB/97 (08-00)

Approved for use through 10/31/2002, OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on February 5, 2004
Date



Signature

Gail L. Winokur

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

2519 USOP - 09/673,958

Response under 37 CFR 1.111

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

02/05/2004

12:03

TAKEDA PHARMACEUTICALS → USPTO GRP1600

NO. 195 D003

RECEIVED
CENTRAL FAX CENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 05 2004

| | | | |
|---------------------------|--|------------|--------------|
| Application No.: | 09/673,958 | Art Unit: | 1635 |
| Filed: | 08/13/2001 | Examiner: | Whiteman, B. |
| 1 st Inventor: | NANBA, Masayoshi | Allowed: | |
| For: | A Human Derived Immortalized Liver Cell Line | Batch: | |
| Atty. Dkt. No. | 2519 USOP | Paper No.: | |

OFFICIAL

Response under 37 CFR 1.111

MAIL STOP NON-FEE Response

Commissioner for Patents

P.O. Box 1450

Arlington, VA 22313-1450

Sir:

In response to the Office Action mailed 1/26/ 2003, Applicants provide the following clarification and respectfully request reconsideration of the claims in view of the amendment and remarks set forth below.

Clarification

L. No Amendment of Claim 2 was intended

Applicants attach herewith a clean set of the claims after Amendment A.

Applicants had mistakenly labeled Claim 2 as (Amended) where in fact no amendment has been made, nor intended to be made.

The pending claims 1 – 5 read as follows: